Involvement of supraspinal imidazoline receptors and descending monoaminergic pathways in tizanidine-induced inhibition of rat spinal reflexes

Journal of Pharmacological Sciences

Volumn 99, Issue 1, 2005, Pages 52-60

  Kino, Yurika ^a   Tanabe, Mitsuo ^a   Honda, Motoko ^a   Ono, Hideki ^a  

^a NAGOYA CITY UNIVERSITY   (Japan)

Author keywords

5,6 dihydroxytryptamine; 6 hydroxydopamine; Imidazoline receptor; Spinal reflex; Tizanidine

Indexed keywords

2 (2 METHOXY 1,4 BENZODIOXAN 2 YL) 2 IMIDAZOLINE; 5,6 DIHYDROXYTRYPTAMINE; ALPHA 2 ADRENERGIC RECEPTOR BLOCKING AGENT; EFAROXAN; IDAZOXAN; IMIDAZOLINE RECEPTOR; NORADRENALIN; OXIDOPAMINE; SEROTONIN; TIZANIDINE; YOHIMBINE;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DRUG ACTIVITY; DRUG EFFECT; MALE; MONOAMINERGIC SYSTEM; MONOSYNAPTIC REFLEX; NONHUMAN; RAT; RECEPTOR AFFINITY; SEROTONIN RELEASE; SPINAL REFLEX;

EID: 25444447395     PISSN: 13478613     EISSN: 13478648     Source Type: Journal    
DOI: 10.1254/jphs.FP0050520     Document Type: Article

References (34)

1. Freitag FG. Preventative treatment for migraine and tension-type headaches: do drugs having effects on muscle spasm and tone have a role? CNS Drugs. 2003;17:373-381.
2. Muramatsu I, Kigoshi S. Tizanidine may discriminate between imidazoline-receptors and alpha 2-adrenoceptors. Jpn J Pharmacol. 1992;59:457-459.
3. Honda M, Sekiguchi Y, Sato N, Ono H. Involvement of imidazoline receptors in the centrally acting muscle-relaxant effects of tizanidine. Eur J Pharmacol. 2002;445:187-193.
4. Bricca G, Dontenwill M, Molines A, Feldman J, Tibirica E, Belcourt A, et al. Rilmenidine selectivity for imidazoline receptors in human brain. Eur J Pharmacol. 1989;163:373-377.
5. 1-imidazoline receptors. Definition, characterization, distribution, and transmembrane signaling. Ann N Y Acad Sci. 1995;763:22-42.
6. Bousquet P. Imidazoline receptors: from basic concepts to recent developments. J Cardiovasc Pharmacol. 1995;26:S1-S6.
7. Bing C, King P, Pickavance L, Brown M, Ziegler D, Kaan E, et al. The effect of moxonidine on feeding and body fat in obese Zucker rats: role of hypothalamic NPY neurones. Br J Pharmacol. 1999;127:35-42.
8. 2-sites. Br J Pharmacol. 1994;112:1065-1070.
9. 2 receptors. Eur J Pharmacol. 1994;262:41-48.
10. 2+ from endoplasmic reticulum, and interaction with exocytotic machinery. Ann N Y Acad Sci. 1999;881:241-252.
11. 2-type imidazoline receptors: an in vivo and in vitro electrophysiological study. Br J Pharmacol. 1998;125:1685-1694.
12. 2-Agonist-induced reduction of noradrenaline release from descending noradrenergic terminals in rat spinal cord: functional relation to spinal motor system. Biomedical Res. 1988;9:169-176.
13. Chan JY, Fung SJ, Chan SH, Barnes CD. Facilitation of lumbar monosynaptic reflexes by locus coeruleus in the rat. Brain Res. 1986;369:103-109.
14. Ono H, Fukuda H. Pharmacology of descending noradrenergic systems in relation to motor function. Pharmacol Ther. 1995;68:105-112.
15. Strahlendorf JC, Strahlendorf HK, Kingsley RE, Gintautas J, Barnes CD. Facilitation of the lumbar monosynaptic reflexes by locus coeruleus stimulation. Neuropharmacology. 1980;19:225-230.
16. Ono H, Fukushima C, Fukuda H. Effect of the centrally acting muscle relaxant tizanidine on spinal reflexes: involvement of descending noradrenergic systems. Jpn J Pharmacol. 1993;62:357-362.
17. Honda M, Ono H. Differential effects of (R)- and (S)-8-hydroxy-2-(di-n- propylamino)tetralin on the monosynaptic spinal reflex in rats. Eur J Pharmacol. 1999;373:171-179.
18. Wallenstein S, Zucker CL, Fleiss JL. Some statistical methods useful in circulation research. Circ Res. 1980;47:1-9.
19. Fung SJ, Barnes CD. Raphe-produced excitation of spinal cord motoneurons in the cat. Neurosci Lett. 1989;103:185-190.
20. Renaud B, Buda M, Lewis BD, Pujol JF. Effects of 5,6-dihydroxytryptamine on tyrosine-hydroxylase activity in central catecholaminergic neurons of the rat. Biochem Pharmacol. 1975;24:1739-1742.
21. Crespi F, Buda M, McRae-Degueurce A, Pujol JF. Alteration of tyrosine hydroxylase activity in the locus coeruleus after administration of p-chlorophenylalanine. Brain Res. 1980;191:501-509.
22. McRae-Degueurce A, Berod A, Mermet A, Keller A, Chouvet G, Joh TH, et al. Alterations in tyrosine hydroxylase activity elicited by raphe nuclei lesions in the rat locus coeruleus: evidence for the involvement of serotonin afferents. Brain Res. 1982;235:285-301.
23. Gorea E, Davenne D, Lanfumey L, Chastanet M, Adrien J. Regulation of noradrenergic coerulean neuronal firing mediated by 5-HT2 receptors: involvement of the prepositus hypoglossal nucleus. Neuropharmacology. 1991;30:1309-1318.
24. Haddjeri N, de Montigny C, Blier P. Modulation of the firing activity of noradrenergic neurones in the rat locus coeruleus by the 5-hydroxtryptamine system. Br J Pharmacol. 1997;120:865-875.
25. Pudovkina OL, Cremers TI, Westerink BH. The interaction between the locus coeruleus and dorsal raphe nucleus studied with dual-probe microdialysis. Eur J Pharmacol. 2002;445:37-42.
26. Baraban JM, Aghajanian GK. Suppression of firing activity of 5-HT neurons in the dorsal raphe by alpha-adrenoceptor antagonists. Neuropharmacology. 1980;19:355-363.
27. Vandermaelen CP, Aghajanian GK. Electrophysiological and pharmacological characterization of serotonergic dorsal raphe neurons recorded extracellularly and intracellularly in rat brain slices. Brain Res. 1983;289:109-119.
28. 2 receptors. Eur J Pharmacol. 1998;353:123-135.
29. 2 receptors. Eur J Pharmacol. 1997;333:9-15.
30. 2 sites. J Pharmacol Exp Ther. 1995;272:681-688.
31. Eglen RM, Hudson AL, Kendall DA, Nutt DJ, Morgan NG, Wilson VG, et al. 'Seeing through a glass darkly': casting light on imidazoline 'I' sites. Trends Pharmacol Sci. 1998;19:381-390.
32. 2-adrenoceptors. CNS Drug Reviews. 2002;8:177-195.
33. ATP channels in pancreatic B-cells. Naunyn Schmiedebergs Arch Pharmacol. 1997;356:410-417.
34. Chan SL, Pallett AL, Clews J, Ramsden CA, Chapman JC, Kane C, et al. Characterisation of new efaroxan derivatives for use in purification of imidazoline-binding sites. Eur J Pharmacol. 1998;355:67-76.